dr. brammer on the importance of mrd in relapsed/refractory all
Published 4 years ago • 70 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
2:30
dr. brammer on data with inotuzumab ozogamicin in all
-
1:47
dr. brammer on the role of stem cell transplantation in all
-
5:51
establishing mrd’s role in all management
-
4:36
mrd in all: prognostic importance and multidisciplinary care
-
7:24
a conversation on mrd in all
-
2:47
damadian, lauterbur, and mansfield: mri machines | heroes of progress | ep. 47
-
39:03
dr. robert c. bransfield, md
-
9:03
iccs education: minimal/measurable residual disease testing (mrd) by flow cytometry in bll
-
5:40
approaching treatment for relapsed/refractory all
-
9:14
blinatumomab for patients with mrd-positive all
-
1:52
dr. brammer on the transformation of stem cell transplant in all
-
6:04
mrd-positive all: personal approaches to treatment
-
1:58
dr. brammer on updates in the treatment landscape for t-cell lymphoma
-
6:16
relapsed/refractory all: evaluating novel agents
-
9:20
mrd to support treatment planning in a young, high-risk all patient
-
1:34
dr. stein on blinatumomab for relapsed/refractory all
-
4:50
importance of mrd testing in acute lymphoblastic leukemia
-
5:40
sensitivity of mrd testing and impact on decisionmaking in all
-
6:42
blinatumomab shown to be beneficial in relapsed/refractory b-precursor acute lymphoblastic leukaemia
-
5:26
selecting a novel therapy for relapsed/refractory all
-
4:22
mrd management in adults with acute lymphoblastic leukaemia
-
5:17
approaches to and the use of mrd in all